A prospective, randomized study to assess the tolerance and efficacy of intramuscular and subcutaneous administration of recombinant follicle- stimulating hormone (Puregon)

Fertility and Sterility

Volumn 67, Issue 2, 1997, Pages 278-283

  Out, Henk J ^a   Reimitz, Paul E ^a   Coelingh Bennink, Herjan J T ^a  

^a Reproductive Medicine Section   (Netherlands)

Author keywords

clinical efficacy; in vitro fertilization; intramuscular; local tolerance; Puregon; recombinant FSH; subcutaneous

Indexed keywords

RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; INFUSION PUMP; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVULATION INDUCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031036396     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(97)81911-5     Document Type: Article

References (17)

1. Olijve W, De Boer W, Mulders JWM, Van Wezenbeek PMGF. Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon). Mol Hum Reprod 1996;2:371-82.
2. Hård K, Mekking A, Damm JBL, Kamerling JP, de Boer W, Wijnands RA, et al. Isolation and structure determination of the intact sialylated N-linked carbohydrate chains of recombinant human follitropin expressed in Chinese hamster ovary cells. Eur J Biochem 1990;193:263-71.
3. Mannaerts B, de Leeuw R, Geelen J, van Ravenstein A, van Wezenbeek P, Schuurs A, et al. Comparative in vitro and in vivo studies on the biological properties of recombinant human follicle stimulating hormone. Endocrinology 1991; 129: 2623-30.
4. Devroey P, Mannaerts B, Smitz J, Coelingh Bennink H, van Steirteghem A. Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens. Hum Reprod 1994;9 1064-9.
5. Out HJ, Mannaerts BMJL, Driessen SGAJ, Coelingh Bennink HJT. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle-stimulating hormone (Puregon vs Metrodin) in in-vitro fertilization. Hum Reprod 1995; 10:2534-40.
6. Rossmanith WG, Sterzik K, Wolf AS. Initial experiences with subcutaneous pulsatile human menopausal gonadotropin administration: successful induction of ovulation in patients with polycystic ovarian disease. Int J Fertil 1991;32:460-6.
7. Nakamura Y, Yoshimura Y, Yamada H, Ubukata Y, Yoshida K, Tamaoka Y, et al. Clinical experience in the induction of ovulation and pregnancy with pulsatile subcutaneous administration of human menopausal gonadotropin: a low incidence of multiple pregnancy. Fertil Steril 1989;51:423-9.
8. Recombinant Human FSH Study Group. Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Fertil Steril 1995;63:77-86.
9. CPMP Working Party on Efficacy of Medicinal Products. Good clinical practice for trials on medicinal products in the European Community. Pharmacol Toxicol 1990;67:361-72.
10. New gonadotropins for old [editorial]? Lancet 1992;340: 1442-3.
11. Le Cotonnec JY, Porchet HC, Beltrami V, Howles C. Comparative pharmacokinetics of two urinary human follicle stimulating hormone preparations in healthy female and male volunteers. Hum Reprod 1993;8:1604-11.
12. Biffoni M, Battaglia A, Borelli F, Cantelmo A. Galli G, Eshkol A. Allergenic potential of gonadotrophic preparations in experimental animals: relevance of purity. Hum Reprod 1994; 9:1845-8.
13. Li TC, Hindle JE. Adverse local reaction to intramuscular injections of urinary-derived gonadotropins. Hum Reprod 1993;8:1835-6.
14. Dore PC, Rice C, Killick S. Human gonadotrophin preparations may cause allergic reaction. Br Med J 1994;308:1509.
15. Navot D, Relou A, Birkenfeld A, Rabinowitz R, Brzezinski A, Margalioth EJ. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1988; 159:210-5.
16. Ulloa-Aguirre A, Cravioto A, Damián-Matsumura P, Jiménez M, Zambrano E, Díaz-Sánchez V. Biological characterization of the naturally occurring analogues of intrapituitary human follicle-stimulating hormone. Hum Reprod 1992;7:23-30.
17. Matikainen T, DeLeeuw R, Mannaerts B, Huhtaniemi I. Circulating bioactive and immunoreactive recombinant human follicle stimulating hormone (Org 32489) after administration to gonadotropin-deftcient subjects. Fertil Steril 1994;61: 62-9.